» Articles » PMID: 20458571

Oral Bisphosphonate Compliance and Persistence: a Matter of Choice?

Overview
Journal Osteoporos Int
Date 2010 May 12
PMID 20458571
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Compliance to oral bisphosphonates is suboptimal, with negative consequences of increased healthcare utilization and less effective fracture risk reduction. Extending dose interval increased adherence only moderately. We used literature derived from multiple chronic conditions to examine the problem of noncompliance with osteoporosis medication. We reviewed the literature on adherence to osteoporosis medication as well as that across multiple chronic conditions to understand what is known about the cause of the poor adherence. Poor compliance to oral medications is due mostly, not to forgetfulness, but to deliberate choice. Gender differences and style of healthcare management also play a role. Preliminary data suggest psychobehavioral interventions may help to improve motivation. We need to understand better reasons for poor compliance before effective interventions can be developed. Forgetfulness is only a small part of poor compliance. Patient preferences must be considered in medication decision making.

Citing Articles

The evaluation of an osteoporosis medication management service in community pharmacy, a cohort study.

Phuong J, Manon S, Moles R, Mason D, Vleeskens C, Rezae F Explor Res Clin Soc Pharm. 2024; 15:100488.

PMID: 39318501 PMC: 11419926. DOI: 10.1016/j.rcsop.2024.100488.


Radiographical Diagnostic Evaluation of Mandibular Cortical Index Classification and Mandibular Cortical Width in Female Patients Prescribed Antiosteoporosis Medication: A Retrospective Cohort Study.

Seki K, Nagasaki M, Yoshino T, Yano M, Kawamoto A, Shimizu O Diagnostics (Basel). 2024; 14(10).

PMID: 38786307 PMC: 11119882. DOI: 10.3390/diagnostics14101009.


Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.

Sahota O, Narayanasamy M, Bastounis A, Paskins Z, Bishop S, Langley T Health Technol Assess. 2024; 28(21):1-169.

PMID: 38634483 PMC: 11056815. DOI: 10.3310/WYPF0472.


Bisphosphonates and Dental Implants: A Systematic Review and Meta-Analysis.

Sulaiman N, Fadhul F, Chrcanovic B Materials (Basel). 2023; 16(18).

PMID: 37763356 PMC: 10532755. DOI: 10.3390/ma16186078.


A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response.

Jamil M, Daneshvar A, Nachawati D, El Sharu H, Meysami A Cureus. 2023; 15(7):e41524.

PMID: 37551226 PMC: 10404464. DOI: 10.7759/cureus.41524.


References
1.
Young R, Taylor J, Friede T, Hollis S, Mason J, Lee P . Pro-active call center treatment support (PACCTS) to improve glucose control in type 2 diabetes: a randomized controlled trial. Diabetes Care. 2005; 28(2):278-82. DOI: 10.2337/diacare.28.2.278. View

2.
Curtis J, Westfall A, Cheng H, Lyles K, Saag K, Delzell E . Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008; 23(9):1435-41. PMC: 2574615. DOI: 10.1359/jbmr.080418. View

3.
Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M . Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008; 336(7653):1114-7. PMC: 2386633. DOI: 10.1136/bmj.39553.670231.25. View

4.
Yood R, Emani S, Reed J, Lewis B, Charpentier M, Lydick E . Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003; 14(12):965-8. DOI: 10.1007/s00198-003-1502-4. View

5.
Haynes R, Ackloo E, Sahota N, McDONALD H, Yao X . Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008; (2):CD000011. DOI: 10.1002/14651858.CD000011.pub3. View